Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RPTR-147 |
Synonyms | |
Therapy Description |
RPTR-147 is a cell therapy that consists of autologous T-lymphocytes primed with PRAME, NYESO-1, SSX2, Survivin, and WT1 tumor associated antigens (TAAs), followed by IL15-Fc nanogel loading, which potentially induces immune response against tumor cells expressing TAAs (Journal for ImmunoTherapy of Cancer 2020;8; Abs nr: 801). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RPTR-147 | RPTR147|RPTR 147|PRIME IL-15 | RPTR-147 is a cell therapy that consists of autologous T-lymphocytes primed with PRAME, NYESO-1, SSX2, Survivin, and WT1 tumor associated antigens (TAAs), followed by IL15-Fc nanogel loading, which potentially induces immune response against tumor cells expressing TAAs (Journal for ImmunoTherapy of Cancer 2020;8; Abs nr: 801). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |